Gaurav Shah, MD
Ophthalmology · San Francisco, CANPI 1972502383
Payments from drug & device makers
Across 484 payments — averaging $1280.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$288K
- Dutch Ophthalmic, USA$75K
- AbbVie$64K
- Novartis$44K
- Biogen$31K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$26K
- plus $93K from 17 others
What the payments were for
- Consulting fees$108,21517%
- Speaking & faculty fees$433,21870%
- Travel & lodging$67,73711%
- Food & beverage$10,3642%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 196 | $287,564 |
| Dutch Ophthalmic, USA | 35 | $74,960 |
| AbbVie(2 entities) | 79 | $63,844 |
| Novartis | 30 | $44,108 |
| Biogen | 13 | $30,574 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 28 | $25,582 |
| Dutch Ophthalmic Research Center (international) B.v. | 9 | $25,341 |
| Carl Zeiss Meditec USA, Inc. | 16 | $18,760 |
| Carl Zeiss Meditec, Inc. | 15 | $18,207 |
| Bausch & Lomb Americas Inc. | 15 | $12,242 |
| Coherus Oncology, Inc. | 5 | $6,305 |
| Beaver-visitec International, Inc. | 1 | $5,600 |
| Genentech USA, Inc. | 14 | $3,257 |
| Regeneron | 7 | $2,145 |
| Lupin Inc. | 1 | $600 |
| Kala Pharmaceuticals, Inc. | 9 | $178 |
| ANI Pharmaceuticals, Inc. | 3 | $77 |
| Neurotech Pharmaceuticals, Inc. | 1 | $70 |
| Harrow Eye, LLC | 1 | $38 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $34 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$146,155
- EYLEA HD$140,790
- EVA Ophthalmic Surgical System$58,473
- OZURDEX$45,474
- EVA, combined machine$41,571
- TISSUEBLUE$23,571
- STELLARIS$23,500
- VISUDYNE$23,130
- CIRRUS HD-OCT$20,961
- RETISERT$20,000
- CLARUS$15,785
- MACUGEN$10,000
- IOLMaster 700$9,234
- VisuMax$7,356
- CIRRUS 6000 with AngioPlex$6,640
- Cimerli$6,255
- XIPERE$5,170
- Humphrey Field Analyzer (HFA3)$4,007
- Humphrey HFA$3,625
- FORUM$3,517
How this compares
$619,572 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 31 | $2,038 |
| Timolol Maleate | 13 | $583 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 27 | $223 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in San Francisco
- Nisha AcharyaSan Francisco$33M
- Daniel SchwartzSan Francisco$8M
- Robert BhisitkulSan Francisco$778K
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.